RIG-I Activators

Imiquimod is a synthetic compound known for its immunomodulatory properties. It functions as a Toll-like receptor 7 (TLR7) agonist, influencing the TLR signaling pathway. Activation of TLR7 can indirectly stimulate the RIG-I pathway through the cross-talk between TLRs and RIG-I-like receptors (RLRs).

Poly(I:C) is a synthetic analog of double-stranded RNA (dsRNA) that mimics viral RNA. This chemical directly activates RIG-I by binding to its RNA helicase domain, initiating a conformational change that leads to the exposure of the CARD domains. This exposes RIG-I to the mitochondrial antiviral signaling protein (MAVS), promoting the formation of the MAVS-RIG-I signaling complex.

DMXAA is a synthetic compound that exhibits antiviral and anti-tumor properties. It acts as a stimulator of the cGAS-STING pathway, indirectly influencing RIG-I activation. DMXAA activates the cGAS enzyme, leading to the production of cyclic GMP-AMP (cGAMP). Subsequently, cGAMP activates STING, initiating a signaling cascade that converges on IRF3 and NF-κB pathways.

Retinoic acid, a derivative of vitamin A, indirectly activates RIG-I through modulation of cellular retinoid receptors. Retinoic acid receptors (RARs) regulate gene expression, and their activation by retinoic acid influences the expression of RIG-I and other antiviral components. This chemical, by regulating transcriptional events related to RIG-I, contributes to the overall cellular defense against viral infections.

Resveratrol, a natural polyphenol found in grapes and red wine, indirectly activates RIG-I by modulating sirtuin 1 (SIRT1) activity. Resveratrol is a known activator of SIRT1, a deacetylase involved in cellular stress responses. SIRT1 influences the acetylation status of key proteins, including those in the RIG-I pathway.

2-Aminopurine is a purine analog that serves as a structural mimic of adenine in RNA. It directly influences RIG-I activation by competitively inhibiting the binding of viral RNA to RIG-I's RNA binding domain. This competitive inhibition prevents the recognition of viral RNA by RIG-I, leading to the dampening of RIG-I activation.

5-Fluorouracil, a pyrimidine analog, indirectly modulates RIG-I activation through its impact on RNA metabolism. This chemotherapeutic agent interferes with RNA synthesis and processing, affecting the availability of viral RNA for recognition by RIG-I. The disruption of RNA synthesis by 5-fluorouracil alters the cellular RNA landscape, indirectly influencing RIG-I activation and the subsequent antiviral response.

Dibutyryl cAMP is a cell-permeable analog of cyclic AMP (cAMP) that activates protein kinase A (PKA) signaling. By stimulating PKA, dibutyryl cAMP indirectly influences RIG-I activation through modulation of the mitochondrial membrane potential. PKA-mediated phosphorylation events affect mitochondrial function, leading to changes in the mitochondrial antiviral signaling protein (MAVS) activity.

5-Aza-2'-deoxycytidine is a demethylating agent that indirectly influences RIG-I activation through epigenetic modulation. It acts by inhibiting DNA methyltransferases, leading to changes in the DNA methylation status of genes, including those involved in the RIG-I pathway.

PMA is a potent activator of protein kinase C (PKC) and indirectly influences RIG-I activation through PKC-mediated signaling. Activation of PKC by PMA leads to downstream phosphorylation events that impact the mitochondrial antiviral signaling protein (MAVS). The modified MAVS activity enhances the formation of the MAVS-RIG-I complex, promoting RIG-I activation and the initiation of antiviral signaling pathways.